251 related articles for article (PubMed ID: 36943460)
1. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG; Yang SYC; Sayad A; Zhao Q; Nguyen LT; Warner K; Sangster AG; Nakatsugawa M; Murata K; Wang BX; Shaw P; Clarke B; Bernardini MQ; Pugh T; Thibault P; Hirano N; Perreault C; Ohashi PS
Cancer Immunol Immunother; 2023 Jul; 72(7):2375-2392. PubMed ID: 36943460
[TBL] [Abstract][Full Text] [Related]
2. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
3. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
5. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
6. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
7. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
8. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
9. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Itoh T; Storkus WJ; Gorelik E; Lotze MT
J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
[TBL] [Abstract][Full Text] [Related]
10. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Front Immunol; 2019; 10():2766. PubMed ID: 31921104
[TBL] [Abstract][Full Text] [Related]
11. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
12. Sensitive and frequent identification of high avidity neo-epitope specific CD8
Bobisse S; Genolet R; Roberti A; Tanyi JL; Racle J; Stevenson BJ; Iseli C; Michel A; Le Bitoux MA; Guillaume P; Schmidt J; Bianchi V; Dangaj D; Fenwick C; Derré L; Xenarios I; Michielin O; Romero P; Monos DS; Zoete V; Gfeller D; Kandalaft LE; Coukos G; Harari A
Nat Commun; 2018 Mar; 9(1):1092. PubMed ID: 29545564
[TBL] [Abstract][Full Text] [Related]
13. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
14. Single-cell sequencing on CD8
Komuro H; Shinohara S; Fukushima Y; Demachi-Okamura A; Muraoka D; Masago K; Matsui T; Sugita Y; Takahashi Y; Nishida R; Takashima C; Ohki T; Shigematsu Y; Watanabe F; Adachi K; Fukuyama T; Hamana H; Kishi H; Miura D; Tanaka Y; Onoue K; Onoguchi K; Yamashita Y; Stratford R; Clancy T; Yamaguchi R; Kuroda H; Doi K; Iwata H; Matsushita H
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37544663
[TBL] [Abstract][Full Text] [Related]
15. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
16. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
17. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee PH; Lang H; Cruz CRY; Hanley PJ; Barrett AJ; Keller MD; Bollard CM
Cytotherapy; 2021 Aug; 23(8):694-703. PubMed ID: 33832817
[TBL] [Abstract][Full Text] [Related]
20. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
